⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALLO News
Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
globenewswire.com
ALLO
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Announces Planned CEO Succession
globenewswire.com
ALLO
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
globenewswire.com
ALLO
Form 8-K
sec.gov
ALLO
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
globenewswire.com
ALLO
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
globenewswire.com
ALLO
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
globenewswire.com
MRK
IPHA
VERU
KURA
INCY
AMGN
PFE
GILD
REGN
AZN
CRSP
BIIB
NTRA
ALLO
KYMR
ADCT
IMUX
CELC
ONON
ABBV
TDOC
BMY
IMVT
GNTX
IMPP
AUTL